EPS for Johnson & Johnson (JNJ) Expected At $2.06 on July, 17

June 27, 2018 - By Nell Hawkins

Johnson & Johnson (NYSE:JNJ) Corporate Logo
During 2018 Q1 the big money sentiment increased to 0.93. That’s change of 0.06, from 2017Q4’s 0.87. 63 investors sold all, 831 reduced holdings as Johnson & Johnson ratio improved. 720 rose positions while 111 funds amassed positions. Funds hold 1.71 billion shares thus 0.80% less from 2017Q4’s 1.72 billion shares.
Haverford Incorporated invested in 3.2% or 65,676 shs. 97,074 are owned by Reilly Finance Ltd Liability. Lifeplan Fincl Gru stated it has 1,168 shs or 0.09% of all its holdings. Brighton Jones Limited Liability Co owns 18,714 shs. Stelac Advisory Svcs Limited Liability Com holds 3,511 shs. Ohio-based Beese Fulmer Invest Mngmt Incorporated has invested 2.71% in Johnson & Johnson (NYSE:JNJ). Round Table Svcs Limited Liability accumulated 4,781 shs. Kdi Cap Partners Limited Liability Corp has 3.4% invested in Johnson & Johnson (NYSE:JNJ). Arcadia Management Mi reported 0.18% in Johnson & Johnson (NYSE:JNJ). Marietta Inv Limited Liability holds 0.19% or 4,962 shs. Deltec Asset Mgmt Ltd Liability Company owns 0.09% invested in Johnson & Johnson (NYSE:JNJ) for 3,425 shs. Edge Wealth Management Limited Liability owns 47,254 shs or 1.61% of their US capital. Franklin Street Advsr Nc holds 86,698 shs or 1.67% of its capital. Eagle Advsrs Limited Co reported 77,460 shs. Mitchell Cap Management owns 4,873 shs.

Johnson & Johnson had 1 insider sale and 0 insider purchases since February 15, 2018. This’s net activity of $20.17 million.

Investors expect Johnson & Johnson (NYSE:JNJ)’s quarterly earnings on July, 17., according to Faxor. Analysts have anticipation on stock’s EPS of $2.06. That’s up 12.57 % from last year’s $1.83 EPS. JNJ’s profit could reach $5.53 billion if the current EPS of $2.06 is accurate. After $2.06 EPS report last quarter, Wall Street now sees 0.00 % EPS growth of Johnson & Johnson. The stock decreased 0.50% or $0.61 during the last trading session, reaching $121.74.Currently Johnson & Johnson is downtrending after 4.75% change in last June 27, 2017. JNJ has also 311,961 shares volume. JNJ underperformed by 17.32% the S&P 500.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Total analysts of 10 have positions in Johnson & Johnson (NYSE:JNJ) as follows: 5 rated it a “Buy”, 1 with “Sell” and 4 with “Hold”. The positive are 50%. Since January 2, 2018 according to StockzIntelligence Inc Johnson & Johnson has 19 analyst reports. On Tuesday, February 6 Wells Fargo maintained Johnson & Johnson (NYSE:JNJ) rating. Wells Fargo has “Buy” rating and $160.0 target. On Monday, February 26 the firm has “Buy” rating by Jefferies given. The company rating was maintained by Credit Suisse on Tuesday, June 12. The company rating was downgraded by JP Morgan on Tuesday, January 2. On Friday, April 13 Jefferies maintained the shares of JNJ in report with “Buy” rating. On Friday, January 12 the rating was maintained by Wells Fargo with “Buy”. On Thursday, May 17 the stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given by Leerink Swann. On Thursday, April 12 the firm has “Buy” rating given by Credit Suisse. On Wednesday, April 18 the rating was maintained by Leerink Swann with “Buy”. On Wednesday, April 18 the stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Deutsche Bank.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide.The firm is worth $326.53 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices.The P/E ratio is 269.34. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

A couple more Johnson & Johnson (NYSE:JNJ) news were released by: Seekingalpha.com which released on June 20, 2018 “Buy Johnson & Johnson”, also Forbes.com on June 20, 2018 released “What Are Johnson & Johnson’s Key Sources Of Revenue?”, the next Fool.com is “Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks” on June 20, 2018. Seekingalpha.com has article titled “How Do You Feel About Johnson & Johnson?: Part IV – Today’s Editors’ Picks”.

Johnson & Johnson (NYSE:JNJ) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: